Navigation Links
Solos Endoscopy, Inc. Reports Significant Sales From Its MammoView® Instrument Line

BOSTON, Dec. 22, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company generated $27,455.52 and $30,103.00 in sales for the months of October and November 2011 respectively. Sales for the two month period were primarily driven by the Company's MammoView® Instrument line accounting for 38.9% of the $57,588.52 in sales revenue for October and November.

Total mammary ductoscopy sales increased 183% from $7925.00 in October to $14,490.00 in November. Solos' MammoView® Instrument line contains 13 different Breast Endoscopy Components which are all featured on the Company's website  The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates.

"We had reported in August how pleased we were with the increase in demand for our MammoView instrument line," stated Bob Segersten, President of Solos Endoscopy, Inc. "The mammary ductoscopy sales in the third quarter as well as for October and November are something the Company will continue to build on as we enter 2012."

The Company recently announced that it finished the 3rd Quarter with a Net Profit of $73,895. Solos Endoscopy has consummated agreements which resulted in the Forgiveness of debt of $299,082 for the Three Months period ending September 30, 2011. The signed settlement agreement and new consulting agreement result in a reduction of ongoing expenses by approximately $40,000 per quarter.

About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Amanda Segersten,
Source: Solos Endoscopy, Inc.

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy Finishes the 3rd Quarter With a Net Profit
2. Solos Endoscopy Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
3. Solos Endoscopy Goes Google
4. Solos Endoscopy Finishes the 3rd Quarter Strong
5. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
6. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
7. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
8. Solos Endoscopy to Reduce Debt by Over $620,000
9. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
10. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
11. Solos Endoscopy, Inc. To Launch New Corporate Website
Post Your Comments:
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
Breaking Medicine Technology:
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
Breaking Medicine News(10 mins):